Trial Profile
A prospective study comparing the pharmacokinetics, efficacy, and side effects of sunitinib in patients with advanced renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacokinetics
- 03 Aug 2018 Status changed from recruiting to completed.
- 05 Aug 2014 New trial record